JP6654137B2 - Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 - Google Patents

Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 Download PDF

Info

Publication number
JP6654137B2
JP6654137B2 JP2016542879A JP2016542879A JP6654137B2 JP 6654137 B2 JP6654137 B2 JP 6654137B2 JP 2016542879 A JP2016542879 A JP 2016542879A JP 2016542879 A JP2016542879 A JP 2016542879A JP 6654137 B2 JP6654137 B2 JP 6654137B2
Authority
JP
Japan
Prior art keywords
hsct
eculizumab
tma
patients
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016542879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531158A (ja
JP2016531158A5 (cg-RX-API-DMAC10.html
Inventor
ジョデル、ソナタ
ラスキン、ベンジャミン、エル．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Children's Hospital Medical Center
Original Assignee
Cincinnati Children's Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Children's Hospital Medical Center filed Critical Cincinnati Children's Hospital Medical Center
Publication of JP2016531158A publication Critical patent/JP2016531158A/ja
Publication of JP2016531158A5 publication Critical patent/JP2016531158A5/ja
Priority to JP2019234471A priority Critical patent/JP7572777B2/ja
Application granted granted Critical
Publication of JP6654137B2 publication Critical patent/JP6654137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016542879A 2013-09-16 2014-09-16 Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 Active JP6654137B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019234471A JP7572777B2 (ja) 2013-09-16 2019-12-25 Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361878119P 2013-09-16 2013-09-16
US61/878,119 2013-09-16
PCT/US2014/055922 WO2015039126A1 (en) 2013-09-16 2014-09-16 Compositions and methods for treatment of hsct-associated thrombotic microangiopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019234471A Division JP7572777B2 (ja) 2013-09-16 2019-12-25 Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2016531158A JP2016531158A (ja) 2016-10-06
JP2016531158A5 JP2016531158A5 (cg-RX-API-DMAC10.html) 2017-11-02
JP6654137B2 true JP6654137B2 (ja) 2020-02-26

Family

ID=52666441

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016542879A Active JP6654137B2 (ja) 2013-09-16 2014-09-16 Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
JP2019234471A Active JP7572777B2 (ja) 2013-09-16 2019-12-25 Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
JP2022014712A Pending JP2022062161A (ja) 2013-09-16 2022-02-02 Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
JP2024118532A Withdrawn JP2024133399A (ja) 2013-09-16 2024-07-24 Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019234471A Active JP7572777B2 (ja) 2013-09-16 2019-12-25 Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
JP2022014712A Pending JP2022062161A (ja) 2013-09-16 2022-02-02 Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
JP2024118532A Withdrawn JP2024133399A (ja) 2013-09-16 2024-07-24 Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法

Country Status (6)

Country Link
US (1) US10815296B2 (cg-RX-API-DMAC10.html)
EP (2) EP3046581B1 (cg-RX-API-DMAC10.html)
JP (4) JP6654137B2 (cg-RX-API-DMAC10.html)
CA (1) CA2921856A1 (cg-RX-API-DMAC10.html)
ES (1) ES2796078T3 (cg-RX-API-DMAC10.html)
WO (1) WO2015039126A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020073531A (ja) * 2013-09-16 2020-05-14 チルドレンズ ホスピタル メディカル センター Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
CN106999559A (zh) * 2014-12-19 2017-08-01 儿童医院医疗中心 与移植相关血栓性微血管病相关的方法和组合物
WO2016200627A1 (en) * 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
TW201718014A (zh) * 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
CN117398458A (zh) * 2015-11-09 2024-01-16 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
JP2023503776A (ja) * 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
JP7821160B2 (ja) * 2020-08-13 2026-02-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
US20250066461A1 (en) * 2021-12-21 2025-02-27 Children's Hospital Medical Center Compositions and methods for treating transplant associated thrombotic microangiopathy in bleeding patients
TW202426048A (zh) * 2022-09-06 2024-07-01 美商阿雷希昂製藥公司 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與
CA3266977A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)
WO2024137904A1 (en) * 2022-12-21 2024-06-27 Children's Hospital Medical Center Improved eculizumab precision dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013664A1 (en) 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
JP6223659B2 (ja) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
JP2011178687A (ja) * 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および／または治療剤
WO2011109338A1 (en) 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Methods and compositions for treating degos' disease
SG11201402490XA (en) 2011-11-23 2014-06-27 Amgen Inc Methods of treatment using an antibody against interferon gamma
CN104870012A (zh) 2012-06-27 2015-08-26 吉安特科技公司 用于炎性疾病的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
US10254288B2 (en) 2013-08-16 2019-04-09 Quidel Corporation Method for species-independent measurement of complement activation in animals
ES2796078T3 (es) * 2013-09-16 2020-11-25 Childrens Hospital Med Ct Composiciones y métodos para el tratamiento de la microangiopatía trombótica asociada al hsct
WO2015070041A1 (en) 2013-11-08 2015-05-14 Icahn School Of Medicine At Mount Sinai Methods for monitoring kidney dysfunction
WO2016200627A1 (en) 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020073531A (ja) * 2013-09-16 2020-05-14 チルドレンズ ホスピタル メディカル センター Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法

Also Published As

Publication number Publication date
JP2016531158A (ja) 2016-10-06
JP7572777B2 (ja) 2024-10-24
EP3046581B1 (en) 2020-04-01
EP3046581A1 (en) 2016-07-27
EP3046581A4 (en) 2017-04-19
ES2796078T3 (es) 2020-11-25
EP3750914A1 (en) 2020-12-16
JP2020073531A (ja) 2020-05-14
WO2015039126A1 (en) 2015-03-19
JP2024133399A (ja) 2024-10-01
JP2022062161A (ja) 2022-04-19
CA2921856A1 (en) 2015-03-19
US20160194386A1 (en) 2016-07-07
US10815296B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
JP7572777B2 (ja) Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
Young et al. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis
Sellmayr et al. Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease
JP7235709B2 (ja) 非典型溶血性尿毒症症候群のバイオマーカータンパク質
Laskin et al. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation–associated thrombotic microangiopathy
Fajgenbaum et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease
Lee et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome
Masterson et al. ABO incompatible renal transplantation without antibody removal using conventional immunosuppression alone
Chen et al. Lipopolysaccharide induces chronic kidney injury and fibrosis through activation of mTOR signaling in macrophages
Saliba et al. Renal impairment and amphotericin B formulations in patients with invasive fungal infections
Song et al. Lipocalin-2 induces NLRP3 inflammasome activation via HMGB1 induced TLR4 signaling in heart tissue of mice under pressure overload challenge
Wen et al. One dose of cyclosporine A is protective at initiation of folic acid-induced acute kidney injury in mice
JP2019047813A (ja) 治療用アポトーシス細胞調製物、その製造方法及びその使用
Berlacher et al. FcγRIIa ligation induces platelet hypersensitivity to thrombotic stimuli
CN1997385B (zh) 膜联蛋白v用于预防动脉血栓和斑块破裂
Abboud et al. Chronic kidney diseases in long-term survivors after allogeneic hematopoietic stem cell transplantation: monitoring and management guidelines
Chen et al. Properdin is a key player in lysis of red blood cells and complement activation on endothelial cells in hemolytic anemias caused by complement dysregulation
Maritati et al. “Eculizumab First” in the management of posttransplant thrombotic microangiopathy
Zhuang et al. Dipyridamole acts as clinical ferroptosis inhibitor to prevent from tissue injury
Mohammed et al. Paroxysmal nocturnal hemoglobinuria: from bench to bed
Vega-Roman et al. Impact of transplantation on neutrophil extracellular trap formation in patients with end-stage renal disease: A single-center, prospective cohort study
Derle et al. Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients
Baird et al. The vacuolar anti-Pseudomonal activity of neutrophil primary granule peptidyl-arginine deiminase enzymes
Tjon et al. Medication-induced nephrotoxicity in children
Glassock et al. Immunoglobulin A nephropathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170919

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180328

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200129

R150 Certificate of patent or registration of utility model

Ref document number: 6654137

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250